Incannex Healthcare Inc. (NasdaqCM: IXHL)
Health Care · Pharmaceuticals · AU
$2.93
-5.48% today · -75.4% 1Y
Incannex Healthcare Inc. (NasdaqCM: IXHL) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $38.89M and employs 12 people.
Over the last twelve months the share price has lost 75.4%, trading between 2.49 and 14.91.
Tweenvest scores Incannex Healthcare Inc. across four factors: quality 37/100, value 35/100. Its strongest factor is quality.
IXHL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $38.89M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.66
- Dividend yield
- —
- Beta (5Y)
- 2.82
- 52-week high
- $14.91
- 52-week low
- $2.49
- Avg volume (3M)
- —
- Shares outstanding
- 12.54M
- Employees
- 12
- Next earnings
- —
About Incannex Healthcare Inc.
Incannex Healthcare Limited is an Australian company dedicated to the research, development, and commercialization of medicinal cannabinoid products. The firm offers pharmaceutical-grade cannabinoid compounds under its proprietary Incannex brand. Its product pipeline includes several key assets: IHL-42X: This compound is currently undergoing Phase II clinical evaluation for the treatment of obstructive sleep apnea (OSA). Incannex partners with The Alfred Hospital and Novotech on this specific clinical program. IHL-216A: Designed to address traumatic brain injury (TBI). Furthermore, the Monash Trauma Group, part of Monash University's Department of Neuroscience, is conducting a study on IHL-216A's protective effects against sports-related concussions. IHL-675A: A unique formulation combining hydroxychloroquine and cannabidiol, developed for both the prevention and management of a range of inflammatory conditions. These include acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), asthma, bronchitis, rheumatoid arthritis, and inflammatory bowel diseases. Originally established in 2001 as Impression Healthcare Limited, the company officially changed its name to Incannex Healthcare Limited in June 2020. Incannex maintains its corporate headquarters in Sydney, Australia.
- ISIN
- US45333F2083
- Listed since
- Mar 2, 2022
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| SCYNEXIS, Inc.NasdaqCM: SCYX | $40.59M | $4.08 | 0.00% |
| Herantis Pharma OyjHLSE: HRTIS | $39.83M | €1.34 | -5.36% |
| BF Biosciences LimitedKASE: BFBIO | $39.61M | PKRs124.18 | -0.40% |
| Filana Therapeutics, Inc.NasdaqCM: FLNA | $39.46M | $0.77 | -5.94% |
| Rekah Pharmaceutical Industry Ltd.TASE: REKA | $38.83M | ₪10.42 | -11.39% |
| Jin Yang Pharmaceutical Co., Ltd.KOSDAQ: A007370 | $38.36M | ₩3,995.00 | +0.50% |
| InnoPharmax Inc.TPEX: 4172 | $38.33M | NT$10.25 | -3.76% |
| RP Bio Inc.KOSDAQ: A314140 | $38.10M | ₩5,910.00 | +2.60% |
Figures last refreshed Oct 11, 2026.